Reductions in Healthcare Resource Utilisation (Hcru) Over 2 Years of Benralizumab Treatment in patients with severe eosinophilic asthma; analysis from the BPAP study

Abstract

Introduction Benralizumab is an anti-interleukin-5 receptor a monoclonal antibody indicated as an add-on maintenance therapy in adult patients with severe eosinophilic asthma (SEA). Herein we present real-data from the Benralizumab Patient Access Programme (BPAP) on the asthma-related, hospital healthcare resource utilisation (HCRU) in patients with severe asthma. Methods The BPAP study is a multi-centre, retrospective chart review study of patients with SEA from eight severe asthma centres in the UK. Data were collected from the medical records of patients receiving their first benralizumab dose between April 2018 and November 2019. Outcomes were assessed using descriptive statistics. HCRU including hospitalisations and emergency department (ED) visits related to exacerbations were described in the 12 months prior to benralizumab initiation (baseline), 1- and 2-years post benralizumab initiation. Patients remaining on treatment were included at each timepoint. Results A total of 276 patients were included. During baseline, 42% of patients had >=1 asthma-related ED attendance; this proportion decreased to 23% at Year 2. Mean (SD) ED attendances reduced from 1.2 (2.2) at baseline to 0.4 (1.0) at Year 2, a relative reduction of 67%. The proportion of patients with >=1 hospitalisation was 39% at baseline, falling to 18% in Year 2. Mean (SD) hospitalisations reduced from 1.0 (1.8) at baseline to 0.4 (1.0) at Year 2, a relative reduction of 70%. For patients with inpatient hospitalisations during the baseline with a recorded length of stay (n=50), median (IQR) length of stay was 6.5 (3.0-17.3) days; this decreased to 2.5 (0.0-8.3) days (n=38) at Year 2; a relative reduction of 62%. There was also a reduction in intensive care admissions from 16/241 (7%) at baseline to 5/209 (2%) at year 2. Conclusions The results show that patients with SEA treated with benralizumab experienced clinically meaningful and sustained reductions in un-scheduled hospital HCRU. Treatment with benralizumab may be associated with >60% reduction in ED visits, hospitalisation and length of stay across all sites. This would reduce pressures on acute services and further work is warranted to investigate the overall economic impact of reduced HCRU. (Table Presented).